Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT05093374 Recruiting - Clinical trials for Exudative Macular Degeneration

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).

NCT ID: NCT05091476 Recruiting - Clinical trials for Age-Related Macular Degeneration

OcuDyne System in the Treatment of AMD

Start date: July 25, 2022
Phase: N/A
Study type: Interventional

Feasibility of the OcuDyne OPTiC System in patients with late-stage non-exudative age-related macular degeneration.

NCT ID: NCT05062486 Recruiting - Clinical trials for Age-related Macular Degeneration

A Study to Evaluate the Safety and Efficacy of RQC for AMD

Start date: July 22, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).

NCT ID: NCT05056025 Recruiting - AMD Clinical Trials

Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.

REVERS
Start date: December 2, 2020
Phase: N/A
Study type: Interventional

A pilot study to establish the efficacy and safety of supplementation with postbiotics in patients with macular degeneration.

NCT ID: NCT05003245 Recruiting - Clinical trials for Age Related Macular Degeneration

Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.

NCT ID: NCT04985487 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Start date: August 18, 2021
Phase:
Study type: Observational

This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.

NCT ID: NCT04929756 Recruiting - Clinical trials for Age Related Macular Degeneration

Eye Movement Rehabilitation in Low Vision Patients

Start date: September 4, 2020
Phase:
Study type: Observational

Approximately 217 million people worldwide currently suffer from low vision, which impacts a broad range of activities of daily living and is associated with depression and increased mortality. Over half of the patients presenting for low vision services have eye disease that affects the fovea and surrounding macula and leads to central vision loss (CVL). People with CVL are forced to use eccentric vision as a substitute for their impaired fovea, however eye movement control and visual function is impaired with eccentric vision. Recent evidence and preliminary results from the investigators show that rehabilitation methods can help improve oculomotor control and this can lead to improved functional outcomes. The investigators have developed new feedback-based training methods that aim to improve eccentric vision use by patients with CVL. In a series of studies, the investigators examine rehabilitation of fixation control, smooth pursuit eye movements that track moving objects and saccadic eye movements that abruptly change the point of regard. The investigators examine how visual feedback, scotoma awareness methods and hand-eye coordination can improve eccentric vision use. Improvements in oculomotor control are quantified with eye tracking methods and associated changes in visual function are quantified with acuity, contrast sensitivity and reading performance. The proposed research therefore develops and translates state-of-the-art methods in basic science to clinical applications. Accomplishing the proposed aims will provide new and improved methods for rehabilitation strategies for visual impairment. The ultimate goal of this proposal is to maximize the residual visual function of people with low vision and to help them to live independently, thereby improving quality of life and minimizing the economic and social burden of visual impairment.

NCT ID: NCT04907409 Recruiting - Clinical trials for Neovascular Age-related Macular Degeneration

Home OCT Fluid Visualization Agreement Study

Start date: June 17, 2021
Phase:
Study type: Observational

This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with scheduled in-office examinations at Week 1, Week 5 and Interim Visits, when applicable, with additional in-office Cirrus volume scans acquired at these office visits. The self-imaging data on the NVHO will be automatically uploaded to the Notal Health Cloud and from there the reconstructed volume scans will sent to the study database.

NCT ID: NCT04882956 Recruiting - Clinical trials for Macula Lutea Degeneration

BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Start date: August 5, 2020
Phase: N/A
Study type: Interventional

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

NCT ID: NCT04863391 Recruiting - Clinical trials for Age Related Macular Degeneration

Telemedicine in Age-Related Macular Degeneration

Start date: July 19, 2020
Phase:
Study type: Observational

This study seeks to evaluate a system for the automated early detection of Age-Related Macular Degeneration (AMD). AMD is a condition in which there is breakdown of the macula of the eye, the part of the retina that is responsible for sharp, central vision. We will take pictures of subjects' eyes using an automated camera. These photographs will be securely transmitted and and then analyzed by a computer program which has been developed in other studies. The outcome of the computer program analysis will be compared with human analysis of these same pictures. If the computer analysis is has good enough accuracy, then this computer system could be used for wide-scale screening for AMD.